Approved Hospital Formulary
Add Formweb to your mobile device
Approved Hospital Formulary
Search results for:
risperiDONE
risperiDONE
| Drug Name | Form | Strength | Non-Formulary | Restricted | Renal Dosing | REMS | Therapeutic Interchange | Notes |
|---|---|---|---|---|---|---|---|---|
| RisperDAL Consta | POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 12.5 mg/2 weeks | ||||||
| RisperDAL Consta | POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 25 mg/2 weeks | ||||||
| RisperDAL Consta | POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 37.5 mg/2 weeks | ||||||
| RisperDAL Consta | POWDER FOR INJECTION, EXTENDED RELEASE, INTRAMUSCULAR | 50 mg/2 weeks | ||||||
| RisperiDONE | SOLUTION, ORAL | 1 mg/mL | ||||||
| RisperiDONE | TABLET, DISINTEGRATING, ORAL | 0.5 mg | ||||||
| RisperiDONE | TABLET, DISINTEGRATING, ORAL | 1 mg | ||||||
| RisperiDONE | TABLET, DISINTEGRATING, ORAL | 2 mg | ||||||
| RisperiDONE | TABLET, ORAL | 0.5 mg | ||||||
| RisperiDONE | TABLET, ORAL | 1 mg | ||||||
| RisperiDONE | TABLET, ORAL | 2 mg | ||||||
| RisperiDONE | TABLET, ORAL | 3 mg | ||||||
| RisperiDONE | TABLET, ORAL | 4 mg |
Last updated: Sep. 23, 2022
- Black Box Warning: Elderly patients with dementia related psychosis
- LASA: ISMP Confused Drug Names
- Hazardous Drugs: NIOSH has determined it is unlikely that risperidone (Risperidal®) poses a carcinogenic, reproductive, or developmental hazard to workers in a healthcare setting and is no longer considered a hazardous drug by NIOSH. (1/10/2019)
Rhazdrugs: risperiDONE
Risperidone